CD274 and non-small cell lung carcinoma: In addition, first-line pembrolizumab monotherapy has been shown to significantly improve overall survival (OS) and progression-free survival (PFS) of patients with untreated metastatic non-small cell lung cancer, as evidenced by PD-L1 tumor proportional scores (TPS) of 50% or higher [41].